Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FES PET/CT in Desmoid Tumors
NCT02374931Phase 1Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Apr 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluoroestradiol f 18 in desmoid tumor, sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Standardized Uptake Value at 24 hours. Started Apr 2015; status: terminated.
02
Drugs
fluoroestradiol f 18
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT02374931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374931.